Longer and better studies on coronary stents required says FDA

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1198, 2008-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA panel says canakinumab not safe enough

By  

Reactions Weekly, Vol. 1, Iss. 1358, 2011-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Current Chantix warnings remain appropriate, says FDA

By  

Reactions Weekly, Vol. 1, Iss. 1375, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

FDA says OK to make preterm birth medication

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 626, 2011-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Uncertainty regarding exemption from infringement for studies after approval, or not required, by the US FDA

By Grossman Jonathan E   Hanish John P  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 4, 2013-07 ,pp. : 435-437

Future Science

Access to resources Recommend Favorite

Drug Eluting Coronary Artery Stents

By  

Current Drug Delivery, Vol. 7, Iss. 5, 2010-12 ,pp. : 421-427

Bentham Science Publishers

Access to resources Recommend Favorite